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Cost-Utility Analyses 
in Orthopaedic Surgery
BY CARMEN A. BRAUER, MD, MSC, FRCSC, ALLISON B. ROSEN, MD, SCD, 
NATALIA V. OLCHANSKI, MS, AND PETER J. NEUMANN, SCD
Investigation performed at Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts
Background: The rising cost of health care has increased the need for the orthopaedic community to understand
and apply economic evaluations. We critically reviewed the literature on orthopaedic cost-utility analysis to determine
which subspecialty areas are represented, the cost-utility ratios that have been utilized, and the quality of the present
literature.
Methods: We searched the English-language medical literature published between 1976 and 2001 for orthopaedic-
related cost-utility analyses in which outcomes were reported as cost per quality-adjusted life year. Two trained review-
ers independently audited each article to abstract data on the methods and reporting practices used in the study as
well as the cost-utility ratios derived by the analysis.
Results: Our search yielded thirty-seven studies, in which 116 cost-utility ratios were presented. Eleven of the stud-
ies were investigations of treatment strategies in total joint arthroplasty. Study methods varied substantially, with only
five studies (14%) including four key criteria recommended by the United States Panel on Cost-Effectiveness in Health
and Medicine. According to a reader-assigned measure of study quality, cost-utility analyses in orthopaedics were of
lower quality than those in other areas of medicine (p = 0.04). While the number of orthopaedic studies has in-
creased in the last decade, the quality did not improve over time and did not differ according to subspecialty area or
journal type. For the majority of the interventions that were studied, the cost-utility ratio was below the commonly
used threshold of $50,000 per quality-adjusted life year for acceptable cost-effectiveness.
Conclusions: Because of limitations in methodology, the current body of literature on orthopaedic cost-utility analy-
ses has a limited ability to guide policy, but it can be useful for setting priorities and guiding research. Future re-
search with clear and transparent reporting is needed in all subspecialty areas of orthopaedic practice.
Level of Evidence: Economic and decision analysis, Level III. See Instructions to Authors for a complete description
of levels of evidence.
linical programs for patients with musculoskeletal dis-
orders are faced with numerous harsh realities: an ag-
ing population requiring more medical intervention,
rapidly emerging newer and often more expensive technolo-
gies, and fixed budgets. Economic evaluation of orthopaedic
surgical treatments is an important area of study that requires
high-quality information if it is to be useful to surgeons and
policy makers.
Cost-utility analysis is a type of economic analysis that is
used to assess the value of an intervention in terms of improv-
ing both quality and quantity of life. (This term as well as
many others used in this field is defined in a glossary at the
end of this article.) “Utility” refers to an individual’s or soci-
ety’s preference for a particular set of health outcomes. Many
tools have been developed to aid researchers in estimating a
patient’s preference for a specific health state, which is then
used to calculate quality of life. These tools include generic in-
struments (e.g., the EQ-5D1, the Health Utilities Index [HUI]2,
and the Quality of Well Being [QWB] Index3), which link in-
formation from general questionnaires with separately de-
rived preferences for health states, and direct measurement
techniques, with which a group of subjects is asked directly to
provide information about their preferences for a set of health
states with use of time-trade-off, standard-gamble, or rating-
scale methods (see Glossary). The goal of all of these ap-
proaches is to derive measures that can then be used in utility
and cost-utility analyses.
Cost-utility analysis is useful for comparing health treat-
ments or programs that may differ in terms of their effects on
morbidity as opposed to only mortality. The incremental cost of
an intervention is compared with the incremental health effects
of the intervention, and the result usually is expressed as a cost
per quality-adjusted life year gained (see Glossary). By combin-
ing quality and duration of life into a single metric, the quality-
adjusted life year allows for comparisons across a broad array of
interventions for the same condition and across different condi-
C
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tions. Consequently, cost-utility analysis is considered the gold
standard for reporting the results of economic evaluations in
the medical literature4-7.
We are not aware of any systematic and comprehensive
audits of the cost-utility literature in orthopaedics. We there-
fore conducted a systematic review of original cost-utility
analyses of orthopaedic surgery in the medical literature. Our
objectives were (1) to provide a resource listing published
cost-utility ratios that can be used by clinicians and policy
makers for decision-making, (2) to identify areas within or-
thopaedic surgery that may benefit from further economic
evaluation, and (3) to critically review the conduct and re-
porting of cost-utility analyses of orthopaedic surgery to iden-
tify opportunities for improvement as these studies play an
increasing role in informing health policy decisions.
Materials and Methods
his study was part of a larger study in which all cost-utility
analyses in medicine were reviewed8,9. Study details, in-
cluding information on the cost-utility ratios9, utility values10,
and reporting practices8, are described elsewhere in detail, and
a comprehensive registry of these studies is available as a pub-
lic-use data file at www.hsph.harvard.edu/cearegistry.
As part of this larger study, a computerized search re-
stricted to the English-language literature was performed with
use of the medical subject headings and/or text keywords
“quality-adjusted,” “QALY,” and “cost-utility.” The search was
conducted with use of Medline, for the years 1976 through
2001. We validated our search findings with use of the Health
Economic Evaluations Database maintained by the British Of-
fice of Health Economics11. One of us (C.A.B.) then reviewed
the articles to determine whether they were orthopaedic-
related and appropriate for inclusion. Two trained reviewers
independently abstracted data on whether or not the interven-
tion, comparison, study perspective, and funding source were
clearly defined; on the utility measurement technique and
source; on whether or not incremental analyses, discounting,
and sensitivity analyses were appropriately reported; and on
the collection and presentation of the cost data and the cost-
utility ratios (see Glossary). The journals were divided into
three groups: general medical or surgical, medical or surgical
subspecialty, and methods or policy. The reviewers met to
reach a consensus on the results, and a third reviewer adjudi-
cated any discrepancies.
The quality of each paper was subjectively rated on a
7-point Likert scale on the basis of criteria derived from
selected recommendations of the United States Panel on Cost-
Effectiveness in Health and Medicine5,6. The panel recom-
mended the use of a societal perspective, community or patient
sources for utility estimates, appropriate incremental compar-
isons, sensitivity analysis, and appropriate discounting of costs
and health benefits at the same rate5.6. To allow comparisons
across countries and between different years, all cost-utility
ratios were converted into real 2002 United States dollars with
use of the foreign exchange factor (Federal Reserve Bank of St.
Louis, St. Louis, Missouri) appropriate to each particular coun-
try for each particular year and with use of the general Con-
sumer Price Index inflator from the United States Bureau of
Labor Statistics. Cost-utility ratios were rounded off to two-
digit precision. An unpaired Student t test assuming unequal
variances was used to compare group means, and the Fisher
exact test was used for comparisons between proportions.
A table was constructed that included a description of
each intervention, the alternative with which it was compared,
and the appropriate target population. This table was sorted
by level of cost-utility, which was divided into five categories:
(1) cost-saving (in terms of money and benefit), (2) cost-utility
ratio of <$20,000 per quality-adjusted life year (considered
to be an excellent value for money⎯i.e., very cost-effective),
(3) cost-utility ratio between $20,000 and $100,000 per qual-
ity-adjusted life year (generally considered to be a good value),
(4) cost-utility ratio of >$100,000 per quality-adjusted life year
(not the best value, but many interventions with such a ratio
are still funded), and (5) dominated (the intervention is less
effective and more costly than the alternative).
Results
ur search revealed thirty-seven studies of interventions
dealing with the musculoskeletal system and ortho-
paedic surgery published between 1989 and 2001, and these
analyses provided a total of 116 cost-utility ratios. Table I lists
the characteristics of these articles.
Total joint arthroplasty was the most commonly studied
intervention. Of the eleven studies dealing with this subject,
five were investigations of the cost-utility of primary total
joint arthroplasty (total hip arthroplasty in four articles and
total knee arthroplasty in one), three articles dealt with the
economic impact of antibiotic prophylaxis for prevention of
infection at the site of an arthroplasty, one focused on strate-
gies for managing infections at the site of a total hip arthro-
plasty, and the remaining two dealt with perioperative issues
(autologous blood donation and duplex venous surveillance).
Nine articles dealt with osteoporosis prevention with pharma-
ceutical intervention: three assessed hormone replacement
therapy; two, bisphosphonates; one, calcium and vitamin D;
and three, other pharmaceutical interventions. Spine surgery
was the topic of five papers, with two papers dealing with the
management of lumbar disc herniation, one involving lumbar
spinal fusion, one dealing with clearance of trauma patients
for cervical spine surgery, and one focusing on neurosurgical
interventions. The last paper was included because it pre-
sented a cost-effectiveness ratio for spinal surgery. One or two
papers each represented the remaining orthopaedic subspe-
cialties, with none in pediatric orthopaedics.
Table II lists the key methodological features of the arti-
cles, and a more comprehensive table providing the method-
ological features of each study is presented in the Appendix.
Adherence to good methodological practices varied: only nine
studies (24%) dealt with utility from a societal perspective by
including some measure of indirect costs (see Glossary). Six of
those studies included costs in terms of patient time and/or
productivity; one included transportation costs; one, costs in
T
O
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terms of caregiver time and productivity; and two, home-care
costs. (Two measures of indirect costs were used in one study.)
Of the thirty-seven studies, thirteen used a Markov model,
which allows for transitions between health states over time.
In eighteen studies (49%) the investigators discounted both
costs and health benefits (see Glossary), and in thirty (81%)
they performed incremental analyses, comparing the costs
and benefits with those of an alternative therapy.
Studies varied with regard to the reporting of costs and
preference weights. The economic data were gathered from a
primary source in only seventeen studies (46%). In most
(twenty-one) of the studies, the models of health benefit were
based on primary sources, and three of these studies were car-
ried out alongside randomized controlled trials. A number of
different methods were used to generate utilities for health
states. The authors of most (nineteen) of the studies relied on
clinical estimates of utilities, derived from the input of clini-
cians, decision analysts, experts, or authors without the use of
any formal methodology. The time-trade-off or standard-
gamble technique was used in three studies, and pre-existing
generic tools such as the EQ-5D1 were employed in eleven.
The general community or the patients themselves were the
most common sources for utility estimates (twenty-seven
studies); health care professionals and/or the authors were the
source in fourteen (38%).
The mean subjective quality score (assigned on a Likert
scale ranging from 1 [low quality] to 7 [high quality]) im-
proved from 3.4 points prior to 1998 to 4.1 points after 1998;
however, this difference was not significant (p = 0.15). There
was no difference in the quality of articles among the different
journal types (mean scores, 4.5 points for the seven general
medical or surgical articles, 3.7 points for the twenty-three or-
thopaedic subspecialty articles, and 3.0 points for the seven
methods or policy articles). The orthopaedic papers had a
lower average quality rating (3.7 points) than did the non-
orthopaedic cost-utility analyses in our larger database, which
had an average quality rating of 4.2 points (p = 0.04). Because
these quality ratings were subjectively assigned (albeit by well-
trained reviewers), a comprehensive chart of key methodolog-
ical practices extracted from each article is presented in the
Appendix to help readers to independently judge the quality
of each study.
Although previous authors have found that studies sup-
ported by industry are more likely to yield favorable results12,13,
we did not find this to be the case for the orthopaedic articles
that we reviewed. The industry-funded studies were as likely
as the government or foundation-funded studies (63% in
both cases) to provide cost-utility ratios of <$50,000 per quality-
adjusted life year (a common threshold below which studies
are considered to be cost-effective). Only five articles (one on
spine surgery and four on total joint arthroplasty), which pre-
sented a total of eight cost-utility ratios, met four key recom-
mendations of the United States Panel on Cost-Effectiveness
in Health and Medicine6,7,14 (use of a societal perspective, utility
estimates based on community or patient sources, appropriate
incremental comparisons, and appropriate discounting of
costs and health benefits at the same rate). Of the eight ratios
(marked with double asterisks in a table in the Appendix) in
these studies, five were <$50,000 per quality-adjusted life year
(considered to be cost-effective), and none of the articles were
funded by industry.
A cost-utility “league table” in the Appendix groups the
interventions in the thirty-seven studies into five categories
ranging from “cost-saving” (less costly and more effective
than the alternative) to “dominated” (more costly and less ef-
fective than the alternative). As noted earlier, the lower the
cost-utility ratio, the better the value of an intervention as it
costs less money to gain a quality-adjusted life year. Eight in-
terventions were cost-saving (cost per quality-adjusted life
year of <$0). Most interventions fell within the ranges of cost-
effectiveness that have commonly been used as thresholds
TABLE I Characteristics of Orthopaedic Cost-Utility 
Analyses Identified in Literature Review
Characteristic
% of Articles 
(N = 37)
Year of publication
1989-1997 43
1998-2001 57
Country of study
United States 54
Sweden 19
Canada 8
United Kingdom 8
Other* 11
Journal type
General medical or surgical 19
Medical or surgical subspecialty 62
Methods or policy 19
Orthopaedic subspecialty
Total joint arthroplasty 30
Osteoporosis 24
Spine 14
Trauma 8
Tumor 5
Foot and ankle 5
Sports medicine 5
Hand and upper extremity 3
Other† 5
Sponsorship‡
Government 43
Foundation 19
Industry (pharmaceutical or medical 
device company)
24
Could not be determined 27
*France, Netherlands, Israel, or Australia. †Medical management
of osteoarthritis or health policy. ‡More than one response was
allowed for each article.
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($20,000 to $100,000 Canadian dollars)15. Thirty-four inter-
ventions were estimated to have a cost-utility ratio of
≤$50,000, and another nine interventions cost between
$50,000 and $100,000 per quality-adjusted life year. The me-
dian was $15,000 per quality-adjusted life year.
Several controversial procedures were found to have rel-
atively high cost-utility ratios (i.e., poorer value), including
antibiotic prophylaxis in certain situations, venous surveil-
lance with phlebography or ultrasound after total joint re-
placement, hormone replacement therapy in relatively young
patients, and laminectomy with fusion and instrumentation
as compared with laminectomy with fusion but no instru-
mentation in patients with spondylolisthesis and spinal steno-
sis. Some procedures in common practice, such as the use of
bisphosphonates for the treatment of osteoporosis in certain
patients and for patients with metastatic breast cancer, had ra-
tios as high as $360,000 per quality-adjusted life year, a value
usually considered to be cost-ineffective. Autologous blood
donation, a common practice in many centers, had a ratio of
$51,000 per quality-adjusted life year for patients undergoing
bilateral or revision total joint replacement in a center with no
change in transfusion practices relative to allogeneic blood. In
a center with increased transfusion of autologous blood (com-
pared with that of allogeneic blood) for patients treated with
primary unilateral total hip replacement, the cost-utility ratios
of autologous donation ranged from $310,000 to $950,000 per
quality-adjusted life year.
Discussion
lthough the volume of published economic evaluations
in the field of orthopaedic surgery is lower than that in
other clinical areas, payers are increasingly demanding evi-
dence of cost-effectiveness. This type of research reflects the
increasing importance of assessing both the costs and the ben-
efits of an intervention. There has been growth in the number
of published economic analyses, and clinicians are being in-
creasingly exposed to these studies. A general understanding
of economic evaluations and a specific awareness of the pub-
lished studies in orthopaedics will be increasingly important
to orthopaedic surgeons as they weigh in on reimbursement
and other policy decisions that affect the field.
Total joint arthroplasty is the most commonly studied
area in the field of orthopaedic surgery. We found six cost-
utility ratios for comparisons of total hip arthroplasty with the
alternative of observation only, and all of the ratios are consid-
ered to indicate cost-effectiveness (below a threshold value of
$50,000 per quality-adjusted life year) by today’s standards.
Osteoporosis is the next most commonly studied area, and,
surprisingly, many of the published ratios indicate that treat-
ment may be cost-ineffective. Half of the cost-utility ratios for
osteoporosis treatment are >$100,000 per quality-adjusted life
year. Additional investigation is required as osteoporosis is a
major public health problem and it will probably continue to
be an area of interest to policy makers.
Spinal surgery, trauma, oncology, pediatric orthopaedics,
and sports medicine are underrepresented in the orthopaedic
cost-utility-analysis literature. Given the burden of disease and
societal costs, there is a need for more information to guide re-
source allocation decisions within these areas of orthopaedics.
The quality of published cost-utility studies is variable
and often poor. The majority of the orthopaedic articles did
not clearly define a perspective; 40% did not explicitly define
the comparison; and, in 24% of the studies, the source of the
health-outcome preferences could not be determined. Most
authors performed sensitivity analysis, reported the method
of cost estimation, discounted appropriately, used incremental
analyses, and stated the threshold that they used. Our findings
suggest the need for improvement in methodology in several
areas. Concerns about the credibility of orthopaedic analyses
may persist in the absence of such improvements.
The modified league table in the Appendix allows clini-
cians and policy makers to quickly view descriptions of the ex-
isting cost-utility analyses in orthopaedic surgery in order to
assess where the reported cost-effectiveness of an intervention
falls. We do not report the actual dollar amount per quality-
adjusted life year for each ratio; such exact numbers might be
misleading, given the variability of the methods that were used
in the studies. The studies in the league table can be examined
A
TABLE II Reporting Practices in Orthopaedic Cost-Utility 
Analyses
Item
% of Articles 
(N = 37)
Study funding source disclosed 73
Framing
Clearly defined intervention 89
Adequate description of comparator 60
Study perspective clearly stated 43
Discount rate for future costs and 
quality-adjusted life years reported
49
Reporting costs
Economic data collected alongside a 
clinical trial or another primary source
46
Authors clearly stated the year of 
monetary units
70
Reporting of preference weights
Preference measurement technique 
reported
68
Source of preferences listed 76
Preference source was patients* 41
Preference source was general 
community*
32
Reporting of results
Incremental analyses appropriately 
reported
81
Sensitivity analyses reported 87
Authors discussed an explicit 
“cost-effective” cutoff
49
*More than one preference source may be used in each study.
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in the context of the methodological practices (also listed in
the Appendix) with which they were performed, allowing the
reader to form his or her own judgment about the validity of a
study’s cost-effectiveness results.
A number of limitations of the present study deserve
mention. The search strategy was limited to selected key
words, and we only included studies in which the cost-utility
ratio was expressed as cost per quality-adjusted life year;
therefore, some well-designed studies may have been omit-
ted16-19. Reviewers were not blinded to the journal in which the
article appeared or to the authors of the article, and this may
have biased the results. The merits of the clinical or economic
model assumptions were not judged; we sought to determine
only whether procedural guidelines for conducting and re-
porting the analysis were followed. Finally, while the method-
ological practices varied among the studies, this fact is not
reflected in the league table presented in the Appendix. The
differences among ratios in league tables can be explained by
looking more closely at key elements of each study. Perspec-
tive, population, the comparison, the method of utility mea-
surement, the country in which the study was performed, the
source of the cost data, and discounting can all affect the re-
sulting ratio. Because of the variability of study methods, the
cost-effectiveness ratios presented in league tables must be
viewed with caution; they provide an aid to health policy
makers but not sufficient evidence on which to base impor-
tant health policy decisions. We addressed this limitation, to
some extent, by placing interventions within a range of cost-
effectiveness values (rather than providing exact cost-utility
ratios) and providing data on study methods for readers who
wish to use that information.
Applying economic evaluation methods to orthopaedic
interventions is a complex undertaking. It requires several dif-
ferent types of expertise, and a number of methodological is-
sues are still unsettled. There are many interventions that have
not yet been studied, and many of those that have been studied
need to be investigated further. The aging of the population and
the development of newer, more expensive technologies ensure
that health care costs will increase. In the past few years, more
explicit considerations of costs have come to the fore. In some
cases, policy makers have explicitly used cost-effectiveness anal-
ysis to make decisions regarding coverage of interventions;
however, in most countries in which cost-utility analyses are
used in policy making, they are applied to the evaluation of
drugs, not devices.
Some private managed-care plans in the United States
have developed and used guidelines20, and the Centers for
Medicare and Medicaid Services have debated the addition of
cost-effectiveness analysis to technology assessment; however,
the regulation has yet to be finalized. In the United Kingdom,
cost-effectiveness analysis is explicitly being used to determine
which new technologies should be introduced into the Na-
tional Health Service, and this process is not limited to phar-
maceuticals. The lack of level-I evidence regarding most
interventions in orthopaedic surgery makes it more difficult
to perform high-quality cost-utility analyses. In the future, or-
thopaedists and industry should be encouraged to provide
better-quality data for health technology assessment with
well-designed prospective, randomized, controlled trials.
There is an urgent need for improving economic evalua-
tion in orthopaedic surgery by using standardized methods
and transparent reporting. As the field develops, it will be im-
portant to assess both the clinical and the economic assump-
tions when one reads the economic literature. It also must be
emphasized that economic analysis should be used to inform
decisions about clinical practice and policy; it should not dic-
tate them14.
Appendix
A table presenting the key methodological criteria of
each study that was analyzed and a cost-utility league ta-
ble are available with the electronic versions of this article, on
our web site at jbjs.org (go to the article citation and click on
“Supplementary Material”) and on our quarterly CD-ROM
(call our subscription department, at 781-449-9780, to order
the CD-ROM).
Glossary
Definitions are adapted in part from reference 14.
Cost-utility analysis: A form of economic evaluation that fo-
cuses on the quality, not just the quantity, of life resulting
from a clinical intervention.
Cost-utility ratio: The ratio is calculated as: (cost of interven-
tion − cost of alternative)/(benefit of intervention – benefit of
alternative). Only the ratios expressed as cost per quality-
adjusted life year were included in the present study. A lower
cost-utility ratio indicates better value. (Less is paid for an in-
crease of one quality-adjusted life year.)
Direct health-care costs: The cost of medical resources con-
sumed (e.g., for physician visits, surgery, and so on).
Discounting: The process of adjusting future costs and future
health benefits to their present value. This is done because fu-
ture costs and benefits are assumed to be worth less to individ-
uals than are present costs and benefits. For example, $10
spent during the second year of a patient’s treatment is worth
less than $10 spent in the present. The $10 spent in the future
needs to be discounted to the present value. If a discount rate
of 5% is used, then the present value would be: $10 × [1/(1 +
0.05)2] = $9.07.
Generic index of health-related quality of life: A standardized
instrument for measuring health outcome that is constructed
by determining preferences for various health states with direct
measurement techniques such as the time-trade-off, standard-
gamble, and rating-scale methods. Some commonly used in-
struments include the EQ-5D1, the Health Utilities Index
(HUI)2, and the Quality of Well Being (QWB) Index3.
Incremental cost: The difference between the cost of an inter-
vention and the cost of the alternative with which it is being
compared.
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Indirect costs: Costs such as lost productivity due to time off
from work during treatment.
Quality-adjusted life years: A generic outcome derived by using
a quality-adjustment weight on the duration of time for which
the patient is affected by an intervention. In the conventional
approach, the utility (the quality-adjustment weight) is multi-
plied by the time spent in that health state, and then those val-
ues are summed to calculate the number of quality-adjusted
life years. For example, if the patient spends one year after the
surgery in a state that is 50% of perfect health (a utility value
of 0.5) and then has a return to perfect health for the next
year, the gain in quality-adjusted life years at two years would
be (0.5 × 1) + (1 × 1) = 1.5 quality-adjusted life years.
Sensitivity analysis: Analysis that determines the impact of
changing variables on the results (e.g., what effect does chang-
ing the hospital costs of an intervention have on the results?).
Standard gamble: A method of determining utility/preference
weights. The respondent is asked to compare life in a given
suboptimal health state with a gamble between two alternate
outcomes: perfect health (denoted as probability p) and death
(denoted as 1 − p). The probabilities in the gamble are varied
until the respondent is indifferent regarding the choice be-
tween the given suboptimal health state and the gamble. The
utility for the given health state is then calculated as: [p × util-
ity (perfect health)] + [(1 − p) × utility (death)]. For example,
a person may be told that he or she can choose to live for his
or her remaining ten years with limited mobility and pain or
risk a therapy (perhaps surgery) that may restore perfect
health (utility = 1) or cause death (utility = 0). If the risk of
death is varied until the person is indifferent regarding the
choice between limited mobility and a 15% chance of death
(the gamble), the utility = (0.85 × 1) + (0.15 × 0), or 0.85.
Time trade-off: A method of determining utility/preference
weights. The respondent is asked to choose between life in a
given suboptimal health state for a fixed amount of time (such
as limited mobility for ten remaining years of life) and life in
perfect health for a shorter period of time (such as perfect mo-
bility for eight years). The life expectancy in perfect health is
varied until the respondent is indifferent regarding the choice
between the two states, and the utility is then calculated as: life
expectancy in perfect health/life expectancy in suboptimal
health (in this example, the utility is 8/10 or 0.8).
Utility states (also referred to as “preference weights”): A mea-
sure of an individual’s or a society’s preference for a particular
set of health outcomes. For example, if a construction worker
and a computer programmer who have sustained a calcaneal
fracture are each asked to rank “having a broken foot” on a
scale of 0 (defined as death) to 1 (defined as perfect health),
their rankings might differ considerably because of the impor-
tance that each attaches to the use of the lower limb. Utilities
can then be used to calculate quality-adjusted life years by
multiplying the utility for a health state by the duration of
time spent in that health state. This allows comparison of out-
comes (in quality-adjusted life years) across different inter-
ventions and different diseases. 
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